Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
free free
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Molecular basis and management of gastrointestinal stromal tumors Bayraktar UD; Bayraktar S; Rocha-Lima CMWorld J Gastroenterol 2010[Jun]; 16 (22): 2726-34Molecularly targeted agents have dramatically impacted the management of several cancers. Targeting KIT has led to a new treatment paradigm in gastrointestinal stromal tumors (GISTs). KIT is a cell surface receptor with tyrosine kinases that, upon binding of its ligand, stem cell factor, activates various signaling pathways. Imatinib and sunitinib, both tyrosine kinase inhibitors directed to KIT, were approved for first- and second-line treatment of metastatic and unresectable GISTs. In this article, we will review the molecular pathogenesis of GISTs followed by a discussion of imatinib and sunitinib's role in the treatment of GISTs. Finally, we will introduce novel therapeutic options for imatinib- and sunitinib-resistant GISTs.|Antineoplastic Agents/*therapeutic use[MESH]|Benzamides[MESH]|Drug Resistance, Neoplasm[MESH]|Gastrointestinal Stromal Tumors/*drug therapy/*genetics/pathology[MESH]|Humans[MESH]|Imatinib Mesylate[MESH]|Indoles/therapeutic use[MESH]|Mutation[MESH]|Piperazines/therapeutic use[MESH]|Protein Kinase Inhibitors/*therapeutic use[MESH]|Proto-Oncogene Proteins c-kit/antagonists & inhibitors/genetics[MESH]|Pyrimidines/therapeutic use[MESH]|Pyrroles/therapeutic use[MESH]|Sunitinib[MESH] |